Divis Laboratories Share Price Analyzed

Divis Laboratories’ share price jumped 2% on Monday, reaching ₹6,579.90 within a broader market downturn. Over the past week, the company’s stock rose by 13%. This increase reflects a positive trend, reaching its highest level since August 1, 2025.

Key Points

• Divis Labs shares rose 2% to ₹6,579.90 on Monday.
• Stock increased 13% in the last week, highest since Aug 1, 2025.
• US Senate approved bill curbing investments in Chinese sectors.
• Bill aims to protect US biotech data from foreign risks.
• Indian CDMOs could benefit from the new US regulations.
• Analysts predict 10% sales growth for Divis Labs in Q2FY26.

The US Senate has passed a bill that targets investments in Chinese companies, particularly in the defense sector. This action aims to safeguard American biotechnology and health data from potential risks, especially those linked to China. This creates opportunities for Indian companies specializing in contract development and manufacturing – known as CDMOs.

The new bill is a revised version of a previous one, addressing concerns about specific company names and insufficient protection for legal processes. Instead of naming specific firms, it empowers the U.S. government to maintain a list of restricted Chinese military companies operating within the United States. This shift signals a long-term strategy to reduce reliance on overseas laboratories and suppliers.

Analysts at Kotak Institutional Equities believe that Divis Laboratories, along with Piramal Pharma, Laurus Labs, and Syngene, will be key beneficiaries of these changes. They anticipate strong growth in the CDMO segment for these companies, particularly in the September 2025 quarter (Q2FY26).

Specifically, analysts predict a 9% year-over-year (YoY) increase in generic active pharmaceutical ingredients (APIs) for Divis Labs, along with 11% growth in contract service and manufacturing (CSM) and 10% in the nutraceuticals segment for Q2FY26.

Kotak’s research indicates that Divis Labs is expected to report overall sales growth of 10% YoY (+7% QoQ) in Q2FY26. Furthermore, the brokerage firm forecasts an improvement in the company’s gross margins to 61.2% QoQ and an EBITDA growth of ₹820 crore (+12% QoQ) with EBITDA margins expanding to 31.7% YoY (+140 bps QoQ).

“Strategic investments and innovation will drive Divis Labs’ continued success in the dynamic pharmaceutical landscape.”